TY - T1的周期性抗血栓形成的急性缺血性中风介入治疗策略JF -神经学乔-神经病学SP - S174 LP - S181做- 10.1212 / WNL。首页0 b013e31826959af六世- 79 - 13补充1 AU - Fadi Nahab盟塔里克·Kass-Hout AU -哈西姆·m·Shaltoni Y1 - 2012/09/25 UR - //www.ez-admanager.com/content/79/1首页3_Supplement_1/S174.abstract N2 -在接受血管内治疗急性缺血性中风的患者,是用来防止远端栓塞进行抗凝治疗,动脉reocclusion或导管栓塞。然而,这必须加以权衡出血性并发症的风险,现有的和持续的缺血或沉默的血管穿孔。在本文中,我们提供了一个概述可用的文学评价抗凝治疗的患者接受血管内治疗急性缺血性中风和讨论这些代理的新兴角色。行动=激活凝血时间;ADP =二磷酸腺苷;AIS =急性缺血性中风;CI =置信区间;GP =糖蛋白;IA =动脉内的; IAT=intra-arterial therapy; IMS=Interventional Management of Stroke; IU=international units; MCA=middle cerebral artery; MERCI=Mechanical Embolus Removal in Cerebral Ischemia; OR=odds ratio; PCI=percutaneous coronary intervention; PROACT=Prolyse in Acute Cerebral Thromboembolism; rpro-UK=recombinant pro-urokinase; rtPA=recombinant tissue plasminogen activator; sICH=symptomatic intracerebral hemorrhage; TIMI=thrombolysis in myocardial ischemia; UK=urokinase ER -